LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aandelen Lijst・Cytokinetics Inc

Cytokinetics Inc

Gesloten

SectorGezondheidszorg

76.75 3.94

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

76.5

Max

77.9

Belangrijke statistieken
By Trading Economics
Inkomsten	123M -183M
Verkoop	16M 18M
Winstmarge	-1,030.87
Werknemers	673
EBITDA	97M -180M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+29.57% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-140M 8.2B
Vorige openingsprijs	72.81
Vorige sluitingsprijs	76.75

Nieuwssentiment

By Acuity

50%

159 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

32.3 / 40.43 Steun & Weerstand

Cytokinetics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 mei 2026, 06:05 UTC

Winsten

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mei 2026, 23:55 UTC

Winsten

Review & Preview: Still Going Strong -- Barrons.com

8 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 20:49 UTC

Winsten

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mei 2026, 20:25 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Net $115M

8 mei 2026, 19:20 UTC

Marktinformatie

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mei 2026, 19:18 UTC

Winsten

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mei 2026, 19:16 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:08 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:05 UTC

Winsten

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mei 2026, 19:02 UTC

Marktinformatie

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mei 2026, 18:51 UTC

Winsten

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mei 2026, 18:49 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 18:41 UTC

Winsten

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mei 2026, 17:14 UTC

Winsten

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mei 2026, 17:04 UTC

Marktinformatie

Zcash Caps Off Parabolic Week -- Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 mei 2026, 15:36 UTC

Marktinformatie

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 mei 2026, 15:20 UTC

Marktinformatie

'Altcoin Season' Indicator on the Rise -- Market Talk

8 mei 2026, 15:20 UTC

Marktinformatie

Winsten

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 mei 2026, 15:05 UTC

Marktinformatie

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 mei 2026, 14:42 UTC

Marktinformatie

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

Peer Vergelijking

Prijswijziging

Cytokinetics Inc Prognose

Koersdoel

By TipRanks

29.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 99.65 USD 29.57%

Hoogste 136 USD

Laagste 67 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cytokinetics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Gebaseerd op 19 analisten die aandelenratings hebben gegeven aan Cytokinetics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

32.3 / 40.43Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

159 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.